Remepy Revenue and Competitors
Employee Data
- Remepy has 43 Employees.
- Remepy grew their employee count by 26% last year.
Remepy's People
| Name | Title | Email/Phone |
|---|
Remepy Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | N/A | 12 | 20% | N/A | N/A |
What Is Remepy?
Remepy is Pioneering Hybrid Drugs™. \nMany medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. \nRemepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. \nThe Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms\n\nRemepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
keywords:N/A
N/A
Total Funding
43
Number of Employees
N/A
Revenue (est)
26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.6M | 43 | -49% | $56.6M |
#2 | $4.7M | 43 | 5% | $28.3M |
#3 | $4.6M | 43 | -56% | $20.2M |
#4 | $4.8M | 43 | 23% | N/A |
#5 | $5M | 43 | -9% | N/A |